FBXO22 and breast carcinoma: After overexpression of Fbxo22, breast cancer metastases were reduced in the lung tissue, yet breast cancer metastases were more obvious after co-treatment of Flag-Fbxo22 and HA-KDM5A (Fig. 6G).